Powering the future of digital surgery

Avamed Synergy is

Avamed Synergy is

Avamed Synergy is anticipation prevention surgical

anticipation

of tumour onset

prevention

of tumour progression

surgical

precision

anticipation

of tumour onset

prevention

of tumour progression

surgical

precision

anticipation

of tumour onset

prevention

of tumour progression

surgical

precision

WHERE DO WE START FROM?

The real problem resides in the complexity of cancer as a disease, as there are hundreds of types of cancers and each one is generated and acts differently in each person.

0 %
Resistance generation
+ 30% generate resistance to treatment
0 %
Resistance generation
+30 % generate resistance to treatment
0 %
Late diagnosis
28 % - 44 % of treatments are often late
0 %
Incorrect treatment
1 in 4 patients recieve initial treatment for another pathology
0 %
Resistance generation
+ 30% generate resistance to treatment
0 %
Late diagnosis
28-44% of treatments are often late
0 %
Incorrect treatment
1 in 4 patients receive initial treatment for another pathology

Faced with this problem, Fluxus, the main project of Avamed Synergy, was born. Fluxus is destined to be the only clinical innovative environment that will be a paradigm shift in predictive oncology, developing a systematic method to predict the future state of an individual tumour.  

Assisted by Artificial Intelligence (AI) and with proprietary native algorithms it provides a tumour-host interface model with multi-scale data and uncertainty quantification.  

Provides insight into morphological properties

It takes into account the spatial arrangement of cells in a specific anatomical location

Provides insight into morphological properties

It takes into account the spatial arrangement of cells in a specific anatomical location

The +2.5 million oncological operations managed by the Spanish public health system that require hospital admission.
+ 0 M
total number of deaths in the operating theatre. High complexity surgery is present in the 2nd cause of death after cardiovascular diseases.
0
total number of complications during high complexity surgery that are avoidable by improving previous decision making.
+ 0
direct hospital cost associated with the approach (GRD's of medical services).
+ 0 MM€
oncological operations managed by the Spanish public health system that require hospital admission.
+ 0 M
total number of deaths in the operating theatre. High complexity surgery is present in the 2nd cause of death after cardiovascular diseases.
0
total number of complications during high complexity surgery that are avoidable by improving previous decision making.
+ 0
direct hospital cost associated with the approach (GRD's of medical services).
+ 0 MM€
oncological operations managed by the Spanish public health system that require hospital admission.
+ 0 M
total number of deaths in the operating theatre. High complexity surgery is present in the 2nd cause of death after cardiovascular diseases.
0
total number of complications during high complexity surgery that are avoidable by improving previous decision making.
+ 0
direct hospital cost associated with the approach (GRD's of medical services).
+ 0 MM€

The future of diagnosis and surgery is collaborative:

human judgement + increased wisdom + digital precision

Our goal is to anticipate the dynamics of tumour growth and its classification, allowing us to eliminate potential unwanted complications in treatment and during surgery, improving results and impact on patients.

Benefits of Fluxus

For oncologists

Although Fluxus is not a diagnostic tool, it improves accuracy in tumour differentiation, which allows better prediction of tumour growth dynamics and improves treatment planning. According to our clinical trial results (non-public medical study), Fluxus reduces false negatives by 70% and helps to avoid overdoses and excessive treatment times. This technology supports personalised medicine, improves patient outcomes and reduces healthcare costs.

For surgeons

Fluxus empowers surgical planning through advanced simulation capabilities, minimising surgical errors and increasing safety. It allows surgeons to rehearse complex surgeries, reducing surgical time by up to 30% and reducing non-tumour tissue resections by 15%. This leads to fewer postoperative complications and better patient outcomes.

For patients

Fluxus provides more detailed information on disease status, possible progression and decisions for longer life expectancy, reduced radiation exposure and better recovery outcomes. Our studies estimate that in the next 10 to 15 years our technology will be able to reduce overdose and overtreatment by 80%, preventing chronic diseases.

For society

Fluxus reduces surgical costs by 12% and overall costs by 29%, through more efficient and accurate treatments. It also optimises healthcare resources by making imaging equipment, such as MRI scanners, more available for other critical needs, improving the overall delivery of healthcare services.

Benefits of Fluxus

For oncologists

Although Fluxus is not a diagnostic tool, it improves accuracy in tumour differentiation, which allows better prediction of tumour growth dynamics and improves treatment planning. According to our clinical trial results (non-public medical study), Fluxus reduces false negatives by 70% and helps to avoid overdoses and excessive treatment times. This technology supports personalised medicine, improves patient outcomes and reduces healthcare costs.  

For surgeons

Fluxus empowers surgical planning through advanced simulation capabilities, minimising surgical errors and increasing safety. It allows surgeons to rehearse complex surgeries, reducing surgical time by up to 30% and reducing non-tumour tissue resections by 15%. This leads to fewer postoperative complications and better patient outcomes.

For patients

Fluxus provides more detailed information on disease status, possible progression and decisions for longer life expectancy, reduced radiation exposure and better recovery outcomes. Our studies estimate that in the next 10 to 15 years our technology will be able to reduce overdose and overtreatment by 80%, preventing chronic diseases.

For society

Fluxus reduces surgical costs by 12% and overall costs by 29%, through more efficient and accurate treatments. It also optimises healthcare resources by making imaging equipment, such as MRI scanners, more available for other critical needs, improving the overall delivery of healthcare services.

Our achievements

Nuestros logros

Nuestros logros

Our latest news

- WHERE WE ARE -

Distrito Digital (Alicante)

Digital District: Avenida de Atoñita Moreno, s/n- Building nº 1, 3RD floor, 03008 Alicante (Spain).

965 316 801 // 965 317 749